Aberdeen Group plc Has $3.04 Million Holdings in Arbutus Biopharma Corporation $ABUS

Aberdeen Group plc lifted its stake in Arbutus Biopharma Corporation (NASDAQ:ABUS) by 110.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 982,527 shares of the biopharmaceutical company’s stock after buying an additional 515,144 shares during the period. Aberdeen Group plc owned about 0.51% of Arbutus Biopharma worth $3,036,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Woodline Partners LP grew its position in Arbutus Biopharma by 173.3% during the 1st quarter. Woodline Partners LP now owns 2,655,738 shares of the biopharmaceutical company’s stock worth $9,269,000 after acquiring an additional 1,684,110 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Arbutus Biopharma by 290.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,075,948 shares of the biopharmaceutical company’s stock worth $7,245,000 after acquiring an additional 1,544,070 shares during the last quarter. Two Seas Capital LP grew its position in Arbutus Biopharma by 8.3% during the 1st quarter. Two Seas Capital LP now owns 9,465,956 shares of the biopharmaceutical company’s stock worth $33,036,000 after acquiring an additional 725,000 shares during the last quarter. ADAR1 Capital Management LLC grew its position in Arbutus Biopharma by 20.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 1,879,114 shares of the biopharmaceutical company’s stock worth $6,558,000 after acquiring an additional 324,312 shares during the last quarter. Finally, Nuveen LLC bought a new stake in Arbutus Biopharma during the 1st quarter worth approximately $1,093,000. 43.79% of the stock is owned by institutional investors and hedge funds.

Arbutus Biopharma Stock Performance

Shares of ABUS opened at $4.51 on Friday. The firm has a market capitalization of $864.57 million, a price-to-earnings ratio of -15.55 and a beta of 1.09. The business’s fifty day moving average price is $4.07 and its two-hundred day moving average price is $3.56. Arbutus Biopharma Corporation has a 52 week low of $2.70 and a 52 week high of $5.10.

Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. The firm had revenue of $10.74 million for the quarter, compared to analyst estimates of $2.21 million. Arbutus Biopharma had a negative return on equity of 59.28% and a negative net margin of 352.24%. As a group, research analysts forecast that Arbutus Biopharma Corporation will post -0.39 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ABUS shares. Wall Street Zen lowered Arbutus Biopharma from a “buy” rating to a “hold” rating in a research report on Friday, September 5th. Chardan Capital restated a “buy” rating and set a $5.00 price target on shares of Arbutus Biopharma in a research report on Monday, August 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Arbutus Biopharma in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Arbutus Biopharma has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.